---
title: "Australian Clinical Labs announces departure of director Grant Jeffery"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281825565.md"
description: "Australian Clinical Labs Ltd has announced the departure of director Grant Jeffery from its board, effective April 7, 2026. The company confirmed that Jeffery held no relevant interests in its securities at the time of his departure, indicating no impact on the company's capital structure. The current analyst rating for ACL stock is a Hold, with a price target of A$2.00. Australian Clinical Labs operates in the medical diagnostics sector, providing laboratory testing and clinical services in Australia."
datetime: "2026-04-07T03:52:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281825565.md)
  - [en](https://longbridge.com/en/news/281825565.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281825565.md)
generator: "portal-rs"
---

# Australian Clinical Labs announces departure of director Grant Jeffery

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.

Australian Clinical Labs has announced that director Grant Jeffery ceased to be a member of its board effective 7 April 2026, with a final director’s interest notice lodged to the ASX. The filing confirms that Jeffery held no relevant interests in the company’s securities or related contracts at the time of his departure, indicating no change to the company’s capital structure or ownership profile arising from this board change.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

**More about Australian Clinical Labs Ltd**

Australian Clinical Labs Limited operates in the medical diagnostics and pathology services sector, providing laboratory testing and related clinical services in Australia. The company supports healthcare providers and patients with diagnostic information used in medical decision-making and ongoing care management.

**Average Trading Volume:** 792,184

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$383.9M

See more data about ACL stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ACL.AU](https://longbridge.com/en/quote/ACL.AU.md)

## Related News & Research

- [ACL: Strong FY26 margin and cash flow, with stable outlook and continued shareholder returns](https://longbridge.com/en/news/296033240.md)
- [Australian Clinical Labs Sets Date and Nomination Deadline for 2026 AGM](https://longbridge.com/en/news/295354918.md)
- [Northern Star Resources GAAP EPS of A$0.11, revenue of A$7.62B](https://longbridge.com/en/news/296522899.md)
- [Can Deterra Royalties (ASX:DRR) Justify Its Valuation On Strong FY2026 Results?](https://longbridge.com/en/news/296349201.md)
- [Australia debt breaches A$1 trillion amid global borrowing spree](https://longbridge.com/en/news/296463179.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**